• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.750 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 840
Open 8.750
Bid (Size) 8.750 (3)
Ask (Size) 8.790 (3)
Prev. Close 8.750
Today's Range 8.750 - 8.750
52wk Range 4.620 - 13.47
Shares Outstanding 59,762,106
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
July 14, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
July 10, 2025
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property

Performance

YTD
+51.4%
+51.4%
1 Month
-5.9%
-5.9%
3 Month
+13.9%
+13.9%
6 Month
+26.1%
+26.1%
1 Year
-31.6%
-31.6%

More News

Read More
Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock
July 08, 2025
Via Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, COEP, AVDX on Behalf of Shareholders
July 05, 2025
From Halper Sadeh LLC
Via GlobeNewswire
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
July 01, 2025
From FN Media Group LLC
Via GlobeNewswire
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
July 01, 2025
Via FinancialNewsMedia
Topics Death
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
June 27, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, CHTR, SAGE, TASK on Behalf of Shareholders
June 25, 2025
From Halper Sadeh LLC
Via GlobeNewswire
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
June 23, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms
June 22, 2025
Via Stocktwits
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
June 18, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
Deep Dive Into Sage Therapeutics Stock: Analyst Perspectives (4 Ratings)
June 17, 2025
Via Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of Shareholders
June 17, 2025
From Halper Sadeh LLC
Via GlobeNewswire
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
June 17, 2025
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
June 17, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
June 17, 2025
Via Benzinga
US Stock Futures Tumble After Trump Threatens 'Real End' To Iran's Nuclear Problem: '...Avoid Getting Whipsawed By Noise,' Says Expert
June 17, 2025
Via Benzinga
Topics Government
Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
June 17, 2025
Via Benzinga
Topics Stocks
Monday's session: top gainers and losers
June 16, 2025
Via Chartmill
S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June
June 16, 2025
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
June 16, 2025
Via Benzinga
Top movers in Monday's session
June 16, 2025
Via Chartmill
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics
June 16, 2025
Via Stocktwits
Topics Government
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday
June 16, 2025
Via Benzinga
These stocks are gapping in today's session
June 16, 2025
Via Chartmill

Frequently Asked Questions

Is Sage Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sage Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sage Therapeutics, Inc. - Common Stock trade on?
Sage Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sage Therapeutics, Inc. - Common Stock?
The ticker symbol for Sage Therapeutics, Inc. - Common Stock is SAGE on the Nasdaq Stock Market
What is the current price of Sage Therapeutics, Inc. - Common Stock?
The current price of Sage Therapeutics, Inc. - Common Stock is 8.750
When was Sage Therapeutics, Inc. - Common Stock last traded?
The last trade of Sage Therapeutics, Inc. - Common Stock was at 07/22/25 04:00 PM ET
What is the market capitalization of Sage Therapeutics, Inc. - Common Stock?
The market capitalization of Sage Therapeutics, Inc. - Common Stock is 522.92M
How many shares of Sage Therapeutics, Inc. - Common Stock are outstanding?
Sage Therapeutics, Inc. - Common Stock has 523M shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap